How will brepocitinib cream compare with established treatments for mild‐to‐moderate eczema?
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Dermatology"
DOI: 10.1111/bjd.21880
Abstract: Brepocitinib (PF-06700841) is a small-molecule dual inhibitor of tyrosine kinase 2 and Janus kinase (JAK)1 previously administered orally in trials of other inflammatory dermatoses. In this issue of the BJD, Landis and coauthors report the… read more here.
Keywords: mild moderate; brepocitinib; brepocitinib cream; moderate eczema ... See more keywords